What the FDA labels say about taking them together
Heparin and lanadelumab
Lanadelumab's FDA label of August 26, 2026 names heparin in its drug interactions section; the heparin labels PlainMeds reads (4) do not name lanadelumab.
Check it at the source: the heparin FDA label on DailyMed (effective November 28, 2025, Fresenius Kabi USA, LLC); the lanadelumab FDA label on DailyMed (effective August 26, 2026).
What does the heparin label say about lanadelumab?
Heparin's label (effective November 28, 2025) and its 3 other brand-application labels do not name lanadelumab in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Heparin Sodium), Fresenius Kabi USA, LLC, effective November 28, 2025 (SPL set d55b4a63-0c04-4874-b74f-9e9b9e8b008c), via openFDA; the full label on DailyMed
What does the lanadelumab label say about heparin?
Lanadelumab label, drug interactionsOnly one patient in the 300 mg every 2 weeks (q2wks) treatment group experienced transient aPTT prolongation ≥1.5x ULN which was confounded by ongoing heparin therapy.
Source: FDA drug label (TAKHZYRO), Takeda Pharmaceuticals America, Inc., effective August 26, 2026 (SPL set 15f99d8c-efe7-4f7d-aa20-0d0f1e30c6e8), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Heparin | Lanadelumab | |
|---|---|---|
| Labeled for | Blood clots (DVT and PE), Atrial fibrillation | n/a |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $1.18 per mL 5,000 unit/mL vial | n/a |
| Shortage now | In shortage | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once